Malkin D - Search Results

1

Mutant p53 reactivation restricts the protumorigenic consequences of wild type p53 loss of heterozygosity in Li-Fraumeni syndrome patient-derived fibroblasts.

Agarwal H, Tal P, Goldfinger N, Chattopadhyay E, Malkin D, Rotter V, Attery A. Agarwal H, et al. Among authors: malkin d. Cell Death Differ. 2024 Jul;31(7):855-867. doi: 10.1038/s41418-024-01307-4. Epub 2024 May 14. Cell Death Differ. 2024. PMID: 38745079 Free PMC article.

2

Li-fraumeni syndrome.

Malkin D. Malkin D. Genes Cancer. 2011 Apr;2(4):475-84. doi: 10.1177/1947601911413466. Genes Cancer. 2011. PMID: 21779515 Free PMC article.

3

Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis.

Light N, Layeghifard M, Attery A, Subasri V, Zatzman M, Anderson ND, Hatkar R, Blay S, Chen D, Novokmet A, Fuligni F, Tran J, de Borja R, Agarwal H, Waldman L, Abegglen LM, Albertson D, Finlay JL, Hansford JR, Behjati S, Villani A, Gerstung M, Alexandrov LB, Somers GR, Schiffman JD, Rotter V, Malkin D, Shlien A. Light N, et al. Among authors: malkin d. Nat Commun. 2023 Jan 5;14(1):77. doi: 10.1038/s41467-022-35727-y. Nat Commun. 2023. PMID: 36604421 Free PMC article.

4

Cell-free DNA from germline TP53 mutation carriers reflect cancer-like fragmentation patterns.

Wong D, Tageldein M, Luo P, Ensminger E, Bruce J, Oldfield L, Gong H, Fischer NW, Laverty B, Subasri V, Davidson S, Khan R, Villani A, Shlien A, Kim RH, Malkin D, Pugh TJ. Wong D, et al. Among authors: malkin d. Nat Commun. 2024 Aug 27;15(1):7386. doi: 10.1038/s41467-024-51529-w. Nat Commun. 2024. PMID: 39191772 Free PMC article.

5

p53 and the Li-Fraumeni syndrome.

Malkin D. Malkin D. Biochim Biophys Acta. 1994 Dec 30;1198(2-3):197-213. doi: 10.1016/0304-419x(94)90014-0. Biochim Biophys Acta. 1994. PMID: 7819275 Review. No abstract available.

6

p53 and the Li-Fraumeni syndrome.

Malkin D. Malkin D. Cancer Genet Cytogenet. 1993 Apr;66(2):83-92. doi: 10.1016/0165-4608(93)90233-c. Cancer Genet Cytogenet. 1993. PMID: 8500106 Review.

7

p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome.

Quesnel S, Verselis S, Portwine C, Garber J, White M, Feunteun J, Malkin D, Li FP. Quesnel S, et al. Among authors: malkin d. Oncogene. 1999 Jul 8;18(27):3970-8. doi: 10.1038/sj.onc.1202783. Oncogene. 1999. PMID: 10435620

8

Identification of a novel PTEN intronic deletion in Li-Fraumeni syndrome and its effect on RNA processing.

Brown LT, Sexsmith E, Malkin D. Brown LT, et al. Among authors: malkin d. Cancer Genet Cytogenet. 2000 Nov;123(1):65-8. doi: 10.1016/s0165-4608(00)00303-4. Cancer Genet Cytogenet. 2000. PMID: 11120338

9

Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.

Malkin D, Chilton-MacNeill S, Meister LA, Sexsmith E, Diller L, Garcea RL. Malkin D, et al. Oncogene. 2001 Jul 27;20(33):4441-9. doi: 10.1038/sj.onc.1204583. Oncogene. 2001. PMID: 11494139

10

Germ line BAX alterations are infrequent in Li-Fraumeni syndrome.

Barlow JW, Mous M, Wiley JC, Varley JM, Lozano G, Strong LC, Malkin D. Barlow JW, et al. Among authors: malkin d. Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1403-6. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15298965

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

381 results

Search Page

Filters